Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update.
Richard A. Larson
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Andreas Hochhaus
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Giuseppe Saglio
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Dong-Wook Kim
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis
Honoraria - Bristol-Myers Squibb; Novartis; Wyeth
Research Funding - Bristol-Myers Squibb; Novartis; Wyeth
Saengsuree Jootar
No relevant relationships to disclose
Philipp D. Le Coutre
Research Funding - ARIAD; Novartis
Expert Testimony - ARIAD; Bristol-Myers Squibb; Novartis
Josy Reiffers
No relevant relationships to disclose
Ricardo Pasquini
No relevant relationships to disclose
Stuart L. Goldberg
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis
Richard E. Clark
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer; Sanofi
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer; Sanofi
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer; Sanofi
Expert Testimony - National Institute of Clinical Excellence - NICE UK
Charisse N. Kemp
Employment or Leadership Position - Novartis
Xiaolin Fan
Employment or Leadership Position - Novartis
Hans D. Menssen
Employment or Leadership Position - Novartis
Timothy P. Hughes
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis
Research Funding - Bristol-Myers Squibb; CSL Limited; Novartis
Hagop M. Kantarjian
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer